With the ink barely dry on outgoing commissioner Marty Makary’s resignation, another top regulator may be heading for the exit at the FDA. | With the ink barely dry on outgoing commissioner Marty ...
Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure marked by mounting ...
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the ...
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche ...
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in ...
Amid apparent overtures from the Trump administration to curb public vaccine criticism ahead of the midterms this fall, the ...
Doceree has bold ambitions to bring a new software category to pharma brand teams, one that reshapes campaign deployment in ...
With a new CEO prepared to take the reins next month and three key launches on deck for 2026 and 2027, Takeda is ready to ...
BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...
Despite a prolonged period of policy uncertainty in the U.S.—and the ripple effects across the global life sciences and ...
As Bicara Therapeutics lines up for a potential accelerated cancer drug approval next year, the biotech has appointed Chris Sarchi as its chief commercial officer. | As Bicara Therapeutics lines up ...
When President Donald Trump rolled out his plan to levy a 100% tariff rate on patented pharmaceutical products and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results